Exalenz Bioscience
Exalenz Bioscience is an Israeli diagnostic company that developed the BreathID urea breath test platform for non-invasive Helicobacter pylori detection. Founded in 2006 and now a subsidiary of Meridian Bioscience, it serves gastroenterologists, primary care physicians, and hospital laboratories worldwide.
- Company typePrivate
- Founded2006
- HeadquartersUnion, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Exalenz Bioscience firmographics
Firmographics- Name
- Exalenz Bioscience
- Legal name
- Exalenz Bioscience Ltd.
- Website
- https://exalenz.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Exalenz Bioscience is an Israeli diagnostic company that developed the BreathID urea breath test platform for non-invasive Helicobacter pylori detection. Founded in 2006 and now a subsidiary of Meridian Bioscience, it serves gastroenterologists, primary care physicians, and hospital laboratories worldwide.
- Ownership category
- akta.pro rank
Exalenz Bioscience industry classification
Industry- Product category
- Gastrointestinal Diagnostic Platforms
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
- akta.pro secondary industry
- Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)
Keywords
Where Exalenz Bioscience is headquartered
LocationHeadquarters
- HQ city
- Union
- HQ country
- United States
- HQ region
- North America
Markets served
Exalenz Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Distribution channels2 records
Marketing channels5 records
Exalenz Bioscience product offering
Product offeringCore offering
Exalenz Bioscience develops and commercializes the BreathID System, a urea breath test platform for non-invasive detection of Helicobacter pylori (H. pylori) infections. The platform is offered in three configurations — BreathID Hp Lab, BreathID Smart, and BreathID Hp — designed for clinical laboratory and point-of-care settings to support H. pylori diagnosis and post-treatment retesting.
Differentiator
Problem solved
Functional benefit
Brands
- BreathID: Urea breath testing platform for H. pylori detection, includes BreathID Hp Lab, BreathID Smart, and BreathID Hp products
Products and services
- BreathID® Hp Lab A diagnostic platform for non-invasive detection of Helicobacter pylori (H. pylori) infection using urea breath test technology, configured for laboratory settings.
- BreathID® Smart
Companies that use Exalenz Bioscience
Customer profileSegments1 record
Ideal customer profiles1 record
Exalenz Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Exalenz Bioscience competitors and assessment
Company assessmentDirect peers
- Kibion (Otsuka Pharmaceutical): Kibion, now owned by Otsuka, is the most direct competitor to Exalenz, marketing the Heliprobe and Diabact UBT urea breath test systems for H. pylori detection; targeting the same gastroenterology and primary care customers with a near-identical diagnostic modality.
- EKF Diagnostics: EKF Diagnostics markets the BreathTest and associated H. pylori urea breath test devices and consumables, directly competing with Exalenz's BreathID platform in hospital lab and point-of-care settings.
- Biohit Oyj: Biohit sells the GastroPanel blood-based H. pylori diagnostic and other GI tests, competing for the same gastroenterologist and primary care budgets as Exalenz's urea breath tests.
Emerging players
- QIAGEN: QIAGEN's molecular diagnostics portfolio includes H. pylori PCR-based stool assays that compete with Exalenz's UBT approach as laboratories shift toward molecular, multiplex GI panels.
Broad incumbents
- DiaSorin: DiaSorin is a larger in-vitro diagnostics company that markets H. pylori stool antigen and serology assays, offering gastroenterologists an alternative non-invasive test modality versus Exalenz's UBT approach.
- Meridian Bioscience: Meridian Bioscience is Exalenz's parent company and the operator of the BreathID line, but it is also a peer in H. pylori diagnostics via its stool antigen, immunoassay, and broader GI pathogen test portfolio targeting the same clinical accounts.
- Thermo Fisher Scientific (Diagnostics): Thermo Fisher's diagnostics division offers H. pylori immunoassays and molecular assays, competing for the same non-invasive testing volume that Exalenz targets with the BreathID platform.
- QuidelOrtho: QuidelOrtho markets a portfolio of immunoassay and rapid infectious disease diagnostics, including H. pylori tests that overlap with the diagnostic use cases served by Exalenz's urea breath platforms.
- Abbott Diagnostics: Abbott offers broad infectious disease and GI diagnostics, including H. pylori serology and stool antigen assays that compete with UBT-based testing for hospital laboratory and physician office demand.
Others
- Bio-Rad Laboratories: Bio-Rad supplies immunoassay reagents and quality controls used by clinical labs running H. pylori serology testing, making it an adjacent peer that benefits from the same non-invasive H. pylori diagnostic workflow Exalenz competes in.
Market position
Customer concentration
Exalenz Bioscience social profiles
Digital presenceExalenz Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Exalenz Bioscience leadership team
Management profileNumber of profiles
Profiles1 record
Exalenz Bioscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Exalenz Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Exalenz Bioscience
What does Exalenz Bioscience do?
Exalenz Bioscience develops and commercializes the BreathID System, a urea breath test platform for non-invasive detection of Helicobacter pylori (H. pylori) infections. The platform is offered in three configurations — BreathID Hp Lab, BreathID Smart, and BreathID Hp — designed for clinical laboratory and point-of-care settings to support H. pylori diagnosis and post-treatment retesting.
Is Exalenz Bioscience a public or private company?
Exalenz Bioscience is a private company. It is classified as corporate owned and is currently acquired.
When was Exalenz Bioscience founded?
Exalenz Bioscience was founded in 2006. It employs 11 to 50 people.
Where is Exalenz Bioscience based?
Exalenz Bioscience is headquartered in Union, United States, in the North America region.
Who are Exalenz Bioscience's main competitors?
Direct peers on record are Kibion (Otsuka Pharmaceutical), EKF Diagnostics and Biohit Oyj. QIAGEN is listed as an emerging player. Broad incumbents are DiaSorin, Meridian Bioscience, Thermo Fisher Scientific (Diagnostics), QuidelOrtho and Abbott Diagnostics. Bio-Rad Laboratories is listed as an others.
Does Exalenz Bioscience have an API?
No public API is recorded for Exalenz Bioscience.
What industry is Exalenz Bioscience in?
Exalenz Bioscience's product category is Gastrointestinal Diagnostic Platforms. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate). Its NAICS code is 334510 and its SIC code is 3841.